Prostate Cancer: Localized: Active Surveillance I (MP23)
Grant R. Pollock,Jiping Zeng,Juan Chipollini,Ardalan E. Ahmad,Canada Toronto,Patrick O. Richard,Ricardo Leão,Henrique Costa Braga,Maria Goldberg,Lisa Komisarneko,Nimit Martin,Omar Timilshina,Shabbir Alhunaidi,Antonio Alibhai,Bashir Samir Al,Hussein Al Awamlh,Xiaoyue Ma,Peter Y. Cai,Neal Patel,Spyridon P. Basourakos,Christopher Gaffney,Rand Wilcox Vanderberg,Jonathan Fainberg,Douglas Scherr,Jim C. Hu,Jonathan E. Shoag,New York,Brennan Timm,Peter Liodakis,Damien Bolton,Gregory S. Jack,Nathan Lawrentschuk,Davide Maffei,Ed Eric Staerman,France Bezannes,Marco Paciotti,Piergiuseppe Colombo,Maria Elefante,L. Domanico,F. Regis,Guilio Bevilacqua,Vittorio Fasulo,Massimo Lazzeri,Rodolfo Hurle,Alberto Saita,Paolo Casale,Nicolò Maria Buffi,Giorgio Guazzoni,John P. Bennett,Tamer Aboushwareb,Natalie Lau,Melissa Conrad Stöppler,Redwood City,Aaron E. Katz,Atsuko Fujihara,Takashi Iwata,Aliasger Shakir,Alessandro Tafuri,Cacciamani Giovanni,Karanvir Gill,Akbar Ashrafi,Los Ángeles,Osamu Ukimura,Mihir Desai,Vinay Duddalwar,Mariana C. Stern,Manju Aron,Suzanne L. Palmer,Inderbir S. Gill,Andre Abreu,Ushasi Naha,Michael R. Abern,Daniel Moreira,Armando Stabile,Isabella Milan,Jeffrey Karnes,Giovanni Motterle,Giorgio Gandaglia,Nicola Fossati,Vito Cucchiara,Simone Scuderi,Francesco Barletta,Giuseppe Fallara,Carlo Andrea Bravi,Elio Mazzone,Daniele Robesti,Donato Cannoletta,Giuseppe Rosiello,Francesco Pellegrino,Sabrina Comana,Paolo Dell’Oglio,Andrea Salonia,Giorgio Brembilla,Antonio Esposito,Francesco Montorsi,Francesco De Cobelli,Alberto Briganti,Nathan Paulson,Tal Zeevi,Maria Papademetris,John A. Onofrey,Preston Sprenkle,Peter A. Humphrey,Lawrence H. Staib,Angelique W. Levi,Peter E. Lonergan,Chang Wook Jeong,Samuel L. Washington,Annika Herlemann,Peter Carroll,Matthew R. Cooperberg,San Francisco,Brijesh Patel,Pierce Massie,John Ogunkeye,Eiftu Haile,Paul Yonover,Justin D. Cohen,Christopher L. Coogan,Michael Leapman,Rong Wang,Xiaomei Ma,Cary P. Gross
DOI: https://doi.org/10.1097/ju.0000000000000856
2020-01-01
Abstract:OBJECTIVE: We evaluated recent trends in the management of low risk prostate cancer (PCa) in the United States (US).Since little is known on factors affecting treatment patterns in era of the Affordable Care Act (ACA), our aims were to measure temporal trends and analyze factors contributing to adoption of surveillance based on state Medicaid expansion status.METHODS: Using the National Cancer Database, we identified men with PCa who resided in the 50 United States or District of Columbia with an incident diagnosis from 2012 to 2016.Men with histologically confirmed low risk PCa, defined as PSA less than 10 ng/ml, Gleason score 6 or less and cT1-T2a, were included.The Cochran Armitage test was used to evaluate trends in surveillance versus treatment across study period and comparisons between expansion and non-expansion states were performed.Univariable and multivariable logistic regression models were used to identify predictors for surveillance.RESULTS: The analytic cohort included 84,340 men.During the study period, surveillance as initial management in the US increased from 13.6% to 32.1% (p<0.01).When comparing by state Medicaid expansion status, expansion states had significantly higher rates of surveillance compared to non-expansion states (Figure 1).The expansion cohort had more white and Hispanic males, higher median income, lower morbidity and education status, and more privately insured and Medicaid patients compared to non-expansion states (all, p<0.05).After adjusting for clinical and demographic variables, Medicaid expansion was a significant predictor for surveillance (p<0.001)(Table 1).CONCLUSIONS: Based on data from 2012-2016, there has been a temporal increase in surveillance as initial management for low risk prostate cancer in the US.State Medicaid expansion was significantly associated with increased rates of surveillance versus treatment.Understanding the impact of payer status on health outcomes can aid in the development of future health care policies aiming to mitigate disparities.